LISA Innovates Crowdfunding Approach for Laboratory Tests
Bringing Together Labs for Advanced FDA-Compliant Assays
The Laboratory Integration Strategic Association (LISA) proudly announces a groundbreaking initiative with the launch of its first crowdfund projects, aimed at empowering laboratories in tackling the evolving FDA regulatory landscape concerning Laboratory Developed Tests (LDTs). This novel approach focuses specifically on urinary tract infection (UTI) assays, setting a new standard for collaboration among accredited clinical labs and the industry.
The Future of UTI Testing
As part of LISA's commitment to innovation, these UTI projects are designed to undergo rigorous analytic validation and clinical verification prepared for FDA submission. By facilitating a cost-effective pathway, LISA enables labs to not only comply with FDA requirements but also enhance the quality of diagnostic services offered to patients.
Benefits of Joining the UTI Crowdfund Projects
Labs that participate in the UTI crowdfund projects will enjoy a suite of benefits tailored to their needs. Some key advantages include:
- Access to high-quality UTI reagents, including cGMP-grade materials critical for meeting certain FDA Quality System Requirements.
- Comprehensive validation and verification data to strengthen submissions.
- Opportunity to be listed on FDA submissions, crucial before reaching Stage 4 of the FDA Final LDT Rule.
- Discounts on essential reagents and FDA-cleared devices.
- A structured pathway through the complexities of the FDA Final LDT Rule.
How Crowdfunding Works at LISA
Unlike traditional crowdfunding avenues, the model at LISA requires laboratories to back projects by purchasing reagents instead of making financial investments. This flexible approach allows labs of all sizes—from those just entering the UTI testing space to established regional labs—to participate at levels they find viable.
A Closer Look at the UTI Assays
Each UTI crowdfund project comprises a multiplex PCR assay that targets four pathogens along with a control, with the first three projects focused on the most common UTI pathogens. This strategy ensures that the solutions developed are not only effective but also tailored to current clinical needs.
Expert Insight from LISA's Leadership
James Gilmore, CEO of LISA, expressed his enthusiasm for the initiative, stating, "We are excited to get these first UTI crowdfund projects into the clinical lab and encourage labs to consider this approach as an important tool for navigating the FDA Final LDT Rule. Upon funding, these assays will undergo extensive verification and validation, distinguishing them from typical LDTs. Furthermore, labs should understand that crowdfunding is beneficial independent of litigation outcomes, as these assays are likely to have improved reimbursement prospects and revenue potential once cleared."
About the Laboratory Integration Strategic Association
The Laboratory Integration Strategic Association (LISA) is dedicated to assisting CAP and COLA-accredited clinical laboratories in navigating the evolving regulatory landscape for Laboratory Developed Tests. Through a pioneering crowdfunding model, LISA drives the development and approval of state-of-the-art assays, enabling laboratories to offer innovative and high-quality diagnostic services.
Contact Information for LISA
For those interested in learning more about LISA and how to become part of this collaborative effort, further details are available on their website. While specific email addresses are confidential, inquires can be sent through the official website.
Frequently Asked Questions
What is the main goal of LISA's crowdfund projects?
The primary aim is to enable laboratories to navigate the FDA regulatory landscape effectively while developing compliant assays for urinary tract infections.
How does LISA support labs in complying with FDA rules?
LISA provides access to essential resources, validation data, and guidance on FDA submissions, simplifying the compliance process for laboratories.
Who can participate in the crowdfund projects?
Any accredited clinical laboratory can participate, regardless of size or experience in UTI testing.
What types of assays are being developed?
The projects focus on multiplex PCR assays that can detect multiple UTI pathogens simultaneously, enhancing diagnostic accuracy.
When can we expect to see the outcomes of these projects?
Upon successful funding and development, extensive validation and verification processes will be conducted, preparing the assays for FDA submission.
